Mariana Puntel

Consejo Nacional de Investigaciones Científicas y Técnicas — Argentina

Biochemistry, Genetics and Molecular Biology · Life Sciences

29h-index2.3kcitations88works8.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Virus-based gene therapy research(44), RNA Interference and Gene Delivery(26), Immunotherapy and Immune Responses(19), CAR-T cell therapy research(19), CRISPR and Genetic Engineering(18)

Publications88 total

Anti-hemagglutinin monomeric nanobody provides prophylactic immunity against H1 subtype influenza A viruses
PLoS ONE·2024· 8 citedOpen Access
Supplementary Figure Legends from Temozolomide Does Not Impair Gene Therapy-Mediated Antitumor Immunity in Syngeneic Brain Tumor Models
2023Open Access
Supplementary Figure 7 from Temozolomide Does Not Impair Gene Therapy-Mediated Antitumor Immunity in Syngeneic Brain Tumor Models
2023Open Access
Supplementary Figure 1 from Temozolomide Does Not Impair Gene Therapy-Mediated Antitumor Immunity in Syngeneic Brain Tumor Models
2023Open Access
Supplementary Figure 5 from Temozolomide Does Not Impair Gene Therapy-Mediated Antitumor Immunity in Syngeneic Brain Tumor Models
2023Open Access
Supplementary Methods from Temozolomide Does Not Impair Gene Therapy-Mediated Antitumor Immunity in Syngeneic Brain Tumor Models
2023Open Access
Data from Temozolomide Does Not Impair Gene Therapy-Mediated Antitumor Immunity in Syngeneic Brain Tumor Models
2023Open Access
Data from Release of HMGB1 in Response to Proapoptotic Glioma Killing Strategies: Efficacy and Neurotoxicity
2023Open Access
Supplementary Figure 5 from Temozolomide Does Not Impair Gene Therapy-Mediated Antitumor Immunity in Syngeneic Brain Tumor Models
2023Open Access
Supplementary Figure 6 from Temozolomide Does Not Impair Gene Therapy-Mediated Antitumor Immunity in Syngeneic Brain Tumor Models
2023Open Access
Supplementary Figure 3 from Temozolomide Does Not Impair Gene Therapy-Mediated Antitumor Immunity in Syngeneic Brain Tumor Models
2023Open Access
Supplementary Figure 1 from Temozolomide Does Not Impair Gene Therapy-Mediated Antitumor Immunity in Syngeneic Brain Tumor Models
2023Open Access
Data from Temozolomide Does Not Impair Gene Therapy-Mediated Antitumor Immunity in Syngeneic Brain Tumor Models
2023Open Access
Supplementary Methods from Temozolomide Does Not Impair Gene Therapy-Mediated Antitumor Immunity in Syngeneic Brain Tumor Models
2023Open Access
Supplementary Figure 2 from Temozolomide Does Not Impair Gene Therapy-Mediated Antitumor Immunity in Syngeneic Brain Tumor Models
2023Open Access
Supplementary Figure 2 from Temozolomide Does Not Impair Gene Therapy-Mediated Antitumor Immunity in Syngeneic Brain Tumor Models
2023Open Access
Supplementary Figure 6 from Temozolomide Does Not Impair Gene Therapy-Mediated Antitumor Immunity in Syngeneic Brain Tumor Models
2023Open Access
Supplementary Figure 4 from Temozolomide Does Not Impair Gene Therapy-Mediated Antitumor Immunity in Syngeneic Brain Tumor Models
2023Open Access
Supplementary Data from Release of HMGB1 in Response to Proapoptotic Glioma Killing Strategies: Efficacy and Neurotoxicity
2023Open Access
Supplementary Figure Legends from Temozolomide Does Not Impair Gene Therapy-Mediated Antitumor Immunity in Syngeneic Brain Tumor Models
2023Open Access
page 1 of 5Next →

Frequent Co-authors

María G. Castro(36), Pedro R. Löwenstein(34), Kurt M. Kroeger(25), Weidong Xiong(18), Chunyan Liu(18), Marianela Candolfi(16), James F. Curtin(15), A.K.M. Ghulam Muhammad(14), Kader Yagiz(10), Donna Palmer(9), Carlos Barcia(8), Sonali Mondkar(8), Gwendalyn D. King(8), Niyati Bondale(8), Mia Wibowo(7), David Foulad(6), Philip Ng(6), Nicholas Sanderson(6), Sandra A. Sciascia(5), Jeffrey M. Zirger(5)